GSK taps new MD Anderson institute in $335m OX40 antibody deal
This article was originally published in Scrip
Executive Summary
The University of Texas MD Anderson Cancer Center is continuing its legacy of licensing oncology discoveries to pharmaceutical companies via a collaboration with GlaxoSmithKline through which the cancer center may earn more than $335 million in upfront and milestone payments plus royalties on sales of therapeutic antibodies that activate OX40 receptors on the surface of T cells to mount an immune system attack.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.